News

From the College of Natural Sciences
A Change in Bacteria’s Genetic Code Holds Promise of Longer-Lasting Drugs

A Change in Bacteria’s Genetic Code Holds Promise of Longer-Lasting Drugs

An alteration in the genetic code of bacteria holds promise for protein therapeutics. Credit: University of Texas at Austin.

By altering the genetic code in bacteria, researchers at The University of Texas at Austin have demonstrated a method to make therapeutic proteins more stable, an advance that would improve the drugs' effectiveness and convenience, leading to smaller and less frequent doses of medicine, lower health care costs and fewer side effects for patients with cancer and other diseases.

The 40 Year-old Discovery Behind A Promising New Flu Drug

The 40 Year-old Discovery Behind A Promising New Flu Drug

A discovery that Robert Krug, a University of Texas at Austin molecular biologist, made decades ago has led to the development of a new drug to fight flu infections more effectively than existing drug treatments.

A Score to Settle with Cancer (Audio)

A Score to Settle with Cancer (Audio)

Jonathan Sessler was a college student when he was first diagnosed with Hodgkin's lymphoma. Fortunately, he was also a chemistry major. After surviving radiation therapy, relapsing and then surviving extremely high doses of what he calls "rat poison" (a.k.a. chemotherapy), his oncologist challenged him: "You're a chemist. Find new cancer drugs."

Ancient Enzyme Could Boost Power of Liquid Biopsies to Detect and Profile Cancers

Ancient Enzyme Could Boost Power of Liquid Biopsies to Detect and Profile Cancers

Scientists are developing a set of medical tests called liquid biopsies that can rapidly detect the presence of cancers, infectious diseases and other conditions from only a small blood sample. Researchers at The University of Texas at Austin are developing a new tool for liquid biopsy that could soon provide doctors with a more complete picture of an individual's disease, improving their chances of finding the best treatment, while also sparing patients the pain, inconvenience and long wait times associated with surgical biopsies.

Stone Named Emerging Inventor of the Year

Stone Named Emerging Inventor of the Year

Everett Stone, a research assistant professor in the Department of Molecular Biosciences at The University of Texas at Austin, has been named the 2017 Emerging Inventor of the Year by the university's Office of Technology Commercialization. The award is given to recognize faculty members who excel in their fields and whose work produces practicable innovations and life-changing discoveries.

Chemists Receive $2 Million to Develop Inexpensive Home Test for Heart Failure

Chemists Receive $2 Million to Develop Inexpensive Home Test for Heart Failure

With the prick of a finger, the new sensor could indicate whether a person has elevated levels of a biomarker associated with heart failure. Credit: iStock.

The National Institutes of Health (NIH) has awarded a team led by Richard M. Crooks, a chemistry professor at The University of Texas at Austin, a $2 million grant to develop an inexpensive, at-home test for people diagnosed with heart failure.

Scientists Discover Powerful Potential Pain Reliever

Scientists Discover Powerful Potential Pain Reliever

Stephen Martin (left) and James Sahn have discovered a new pain reliever that acts on a previously unknown pain pathway. Photo Credit: Courtesy of Stephen Martin.

A team of scientists led by chemists Stephen Martin and James Sahn at The University of Texas at Austin have discovered what they say is a powerful pain reliever that acts on a previously unknown pain pathway. The synthetic compound, known as UKH-1114, is as effective at relieving neuropathic pain in injured mice as a drug widely used for pain relief called gabapentin, but it works at a much lower dose, with longer duration of action.

UT Austin Leads $29 Million Alcoholism Treatment Consortium

UT Austin Leads $29 Million Alcoholism Treatment Consortium

The National Institutes of Health has awarded an international consortium seeking better pharmaceutical treatments for alcoholism a five-year grant totaling $29 million. The administrative headquarters and several of the projects will be at The University of Texas at Austin, which will receive $8.5 million of the total.

Unlocking the Mysteries of Life-Changing Hepatitis C Drugs

Unlocking the Mysteries of Life-Changing Hepatitis C Drugs

Researchers at the University of Texas at Austin have for the first time revealed how a group of drugs that are being developed to treat hepatitis C works. Pharmaceutical companies might be able to apply these new insights to future drugs designed to address a deadly disease.

Drug Engineered at UT Austin to Treat Anthrax Gains FDA Approval

Drug Engineered at UT Austin to Treat Anthrax Gains FDA Approval

Researchers at The University of Texas at Austin successfully culminated years of work when a drug they engineered for the treatment and prevention of inhalational anthrax — the anthrax antitoxin obiltoxaximab — received approval March 21 from the U.S. Food and Drug Administration (FDA).